ArticleAmerican journal of public health2017
Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.
Article in American journal of public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis.PharmacoEconomics · 2025Article
- Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.PloS one · 2025Article
- Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.JAMA health forum · 2024Article
- Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.Addiction science & clinical practice · 2023Article
- Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C.Journal of viral hepatitis · 2023Article
- Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.JAMA network open · 2023Article
- Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.JAMA network open · 2022Article
- Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.Journal of health politics, policy and law · 2022Article
- Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment.Gastroenterology research · 2022Article
- Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.Drug and alcohol dependence reports · 2022Article
- Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured.American journal of preventive medicine · 2022Article
- Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor.Journal of public health (Oxford, England) · 2022Article
- Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.JAMA network open · 2021Article
- Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.JAMA health forum · 2021Article
- Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.Journal of managed care & specialty pharmacy · 2021Article
- Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.Journal of the National Medical Association · 2021Article
- Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study.Journal of viral hepatitis · 2021Article
- Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020Review
- Comparing direct acting antivirals for hepatitis C using observational data - Why and how?Pharmacology research & perspectives · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicaid programs provide health insurance coverage for many patients with hepatitis C, a public health problem for which effective but very expensive treatments are now available. Facing constrained budgets, most states adopted prior authorization criteria for sofosbuvir, the first of these agents. Using fee-for-service utilization data from 42 Medicaid programs in 2014, we found that strict behavioral criteria-those that limited coverage on the basis of drug or alcohol use and included specific abstinence or treatment requirements-were associated with significantly less spending on sofosbuvir. Despite the potential cost savings, such criteria raise troubling questions in terms of public health as well as medical ethics, clinical evidence, and potentially federal law. Decision-makers should reject these requirements in Medicaid coverage policy and pursue national and state policy strategies to balance short-term budgetary realities with long-term public health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.